Program
flonoltinib
Also written as “Flonoltinib 75mg”, “Flonoltinib 100mg” and “flonoltinib 25mg”.
Its studies are mostly in Myeloproliferative Disorders · Polycythemia Vera, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chengdu Zenitar Biomedical Technology | 64 open or running | phase 3since Dec 19, 2025 | Nov 29, 2021 | Dec 30, 2026phase 1 · NCT07768111 |
| Guizhou Bailing Group Pharmaceutical | 10 open or running | phase 1since Aug 12, 2021 | Aug 12, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 12, 2021First study: phase 1 study in Myeloproliferative DisordersNew to Guizhou Bailing Group PharmaceuticalGuizhou Bailing Group Pharmaceutical · NCT05115344
- Nov 29, 2021Chengdu Zenitar Biomedical Technology's first study: phase 2 study in Myeloproliferative DisordersNew to Chengdu Zenitar Biomedical TechnologyChengdu Zenitar Biomedical Technology · NCT05153343 · 31 enrolled · China
- Jun 7, 2024Phase 2 study in MF,PMF,PPV-MF,PET-MFChengdu Zenitar Biomedical Technology · NCT06457425 · 75 enrolled · China
- Sep 24, 2025Phase 2 study in Polycythemia VeraChengdu Zenitar Biomedical Technology · NCT07232290 · 60 planned · China
- Dec 19, 2025Phase 3 study in MFPhase 3 reachedChengdu Zenitar Biomedical Technology · NCT07317700 · 105 planned · China
- May 12, 2026Phase 1 study in MBChengdu Zenitar Biomedical Technology · NCT07612306 · 6 enrolled · China
- Aug 5, 2026Phase 1 study in Drug Interaction ResearchChengdu Zenitar Biomedical Technology · NCT07768111 · 40 planned · China
Ahead
- Dec 30, 2026Primary completion: phase 1 study in Drug Interaction ResearchChengdu Zenitar Biomedical Technology · NCT07768111
- Jul 30, 2027Primary completion: phase 2 study in Polycythemia VeraChengdu Zenitar Biomedical Technology · NCT07232290
- Dec 30, 2027Primary completion: phase 3 study in MFChengdu Zenitar Biomedical Technology · NCT07317700
TargetBeta
“Flonoltinib Maleate (FM), a triple target inhibitor of JAK2/FLT3/CDK6, has the potential to inhibit JAK2 signaling pathway activity and treat bone marrow proliferative tumors.”study text, by rule · the study
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07768111Drug Interaction Research · China | 1 | Not yet recruiting | Chengdu Zenitar Biomedical Technology | Dec 30, 2026 | 40 |
| NCT07612306MB · China | 1 | Completed | Chengdu Zenitar Biomedical Technology | Jul 25, 2026 | 6 |
| NCT07317700MF · China | 3 | Recruiting | Chengdu Zenitar Biomedical Technology | Dec 30, 2027 | 105 |
| NCT07232290Polycythemia Vera · China | 2 | Recruiting | Chengdu Zenitar Biomedical Technology | Jul 30, 2027 | 60 |
| NCT06457425MF,PMF,PPV-MF,PET-MF · China | 2 | Active, not recruiting | Chengdu Zenitar Biomedical Technology | Nov 26, 2025 | 75 |
| NCT05153343Myeloproliferative Disorders · China | 2 | Completed | Chengdu Zenitar Biomedical Technology | Nov 29, 2023 | 31 |
| NCT05115344Myeloproliferative Disorders | 1 | Withdrawn | Guizhou Bailing Group Pharmaceutical | Dec 29, 2022 | 0 |
How it is read
Names in the registry
- “Flonoltinib 75mg”, 3 entries
- “Flonoltinib 100mg”, 2 entries
- “flonoltinib 25mg”, 2 entries
- “flonoltinib 50mg”, 2 entries
- “flonoltinib 100mg”, 2 entries
Conditions, from the studies’ own filings
- Myeloproliferative Disorders, 2 studies
- Polycythemia Vera, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.